Potentiation of pro-inflammatory cytokine suppression and survival by microencapsulated dexamethasone in the treatment of experimental sepsis

Journal of Drug Targeting

Volumn 19, Issue 9, 2011, Pages 752-760

  Uddin, Mohammad N ^a   Siddiq, Aladin ^b   Oettinger, Carl W ^a   D'Souza, Martin J ^a  

^a MERCER UNIVERSITY   (United States)

^b Robert C Byrd Center for Pharmacy Education   (United States)

Author keywords

Corticosteroids; Cytokine; IL 1 ; Microsphere; Septic shock; TNF

Indexed keywords

ALBUMIN MICROSPHERE; CYTOKINE; DEXAMETHASONE; GENTAMICIN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENTIATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROENCAPSULATION; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; SEPTIC SHOCK; SURVIVAL RATE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GENTAMICINS; HUMANS; INTERLEUKIN-1BETA; MALE; MICROSPHERES; PARTICLE SIZE; PERITONITIS; RATS; RATS, SPRAGUE-DAWLEY; SHOCK, SEPTIC; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054680663     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.561856     Document Type: Article

References (40)

1. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. (2002). Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis of microspheres. J Control Release, 79, 29-40 (Pubitemid 34164159)
2. Almawi WY, Melemedjian OK. (2002). Negative regulation of nuclear factor-kB activation and function by glucocorticoids. J of Mol Endocrinology, 28, 69-78 (Pubitemid 34428757)
3. Bejugam NK, Uddin AN, Gayakwad SG, DSouza MJ. (2008). Formulation and evaluation of albumin microspheres and its enteric coating using a spray-dryer. J Microencapsul, 25, 577-583
4. Cetinkaya RA, Görenek L, Coskun O, Eyigün CP, Senses Z, Ide T, Kili S. (2009). The effect of methylprednisolone on treatment in rats with induced sepsis. Clin Exp Med, 9, 45-50
5. Chatterjee S, Premachandran S, Shukla J, Poduval TB. (2007). Synergistic therapeutic and L-arginine in lipopolysaccharideinduced septic shock. J Surgical Res 140, 99-108 (Pubitemid 46669538)
6. Crinelli R, Antonelli A, Bianchi M, Gentilini L, Scaramucci S, Magnani M. (2000). Selective inhibition of NF-?B activation and TNF-a production in macrophages by red blood cell-mediated delivery of dexamethasone. Blood Cells, Molecules and Diseases 26, 211-222
7. DAcquisto F, May MJ, Ghosh S. (2002). Inhibition of nuclear factor kappa B (NF-B): an emerging theme in anti-inflammatory therapies. Mol Interv, 2, 22-35
8. DSouza MJ, Jin Z, Oettinger CW. (2005). Treatment of experimental septic shock with microencapsulated antisense oligomers to NF-?B. J Interferon Cytokine Res, 25, 311-320 (Pubitemid 40911382)
9. DSouza MJ, Oettinger CW, Milton GV. (1999a). Prevention of lethality and suppression of proinflammatory cytokines in experimental septic shock by microencapsulated CNI-1493. J Interferon Cytokine Res, 19, 1125-1133 (Pubitemid 29502779)
10. DSouza MJ, Oettinger CW, Milton GV. (2000). Microspheres containing neutralizing antibodies to tumor necrosis factor-? and interleukin-1? protect rats from staphlococcus aureus-induced peritonitis. J Interferon Cytokine Res, 20, 907-913
11. DSouza MJ, Oettinger CW, Shah A, Tipping PG, Huang XR, Milton GV. (1999b). Macrophage depletion by albumin microencapsulated clodronate: attenuation of cytokine release in macrophagedependent glomerulonephritis. Drug Dev Ind Pharm, 25, 591-596 (Pubitemid 29186290)
12. De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W, Haegeman G. (1997). Glucocorticoid-mediated repression of nuclear factor-kB-dependent transcription involves direct interference with transactivation. Proc Natl Acad of Sci, 94, 13504-13509 (Pubitemid 28009612)
13. Dellinger RP. (2008). Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock. Crit Care Med, 36, 296-327
14. Finfer S. (2008). Corticosteroids in septic shock. N Engl J Med, 358, 188-190
15. Gayakwad SG, Bejugam NK, Akhavein N, Uddin NA, Oettinger CE, DSouza MJ. (2009). Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-kappaB encapsulated albumin microspheres. J Microencapsul, 15, 1-9
16. Hayashi R, Wada H, Ito K, Adcock IM. (2004). Effects of glucocorticoids on gene transcription. Eur J Pharmacol, 500, 51-62 (Pubitemid 39303996)
17. Kwame GY, DSouza MJ. (2009). Evaluation of albumin microspheres as oral delivery system for Mycobacterium tuberculosis vaccines. Journal of Microencapsulation, 26, 166-179
18. Makino K, Yamamoto N, Higuchi K, Harada N, Ohshima H, Terada H. (2003). Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of size and surface properties of the microspheres. Colloids and Surfaces B: Biointerfaces, 27, 33-39 (Pubitemid 35346319)
19. Malvern Instruments Ltd. (2011). Zeta potential - An introduction in 30 minutes (KB000734). Available at http://www.malvern.com
20. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. (2004). Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med, 141, 47-56
21. Neeck G, Renkawitz R, Eggert M. (2002). Molecular aspects of glucocorticoid hormone action in rheumatoid arthritis. Cytokines Cell Mol Ther, 7, 61-69 (Pubitemid 36187839)
22. Nissen RM, Yamamoto KR. (2000). The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev, 14, 2314-2329
23. Oettinger C, DSouza M. (2003). Microencapsulation of tumor necrosis factor oligomers: a new approach ton proinflammatory cytokine inhibition. J Interferon Cytokine Res, 23, 533-543 (Pubitemid 37130076)
24. Oettinger CW, DSouza MJ, Akhavein N, Peer GT, Taylor GT, Kinasewitz GT. (2007). Pro-inflammatory cytokine inhibition in the primate using microencapsulated antisense to NF-?B. J Microencapsul, 24, 337-348 (Pubitemid 47381831)
25. Oettinger CW, DSouza M, Milton GV. (1999). Targeting macrophages with microspheres containing cytokine-neutralizing antibodies prevents lethality in gram negative peritonitis. J Interferon Cytokine Res, 19, 33-40 (Pubitemid 29070230)
26. Oliver JC, Bland LA, Oettinger CW, Arduino MJ, McAllister SK, Aguero SM, Favero MS. (1993). Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res, 12, 115-120 (Pubitemid 23141784)
27. Reinhart K, Waheedullah K. (2001). Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned 29, 121-125
28. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS. (1995). Characterization of mechanisms involved in transrepression of NF-?B by activated glucocorticoid receptors. Mol and Cell Biol, 15, 943-953
29. Silva AT, Bayston KF, Cohen J. (1990). Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock. J Infect Dis, 162, 421-427 (Pubitemid 20239958)
30. Siwale RC, Oettinger CW, Addo R, Siddiq A, DSouza MJ. (2009a). The effect of intracellular delivery of catalase and antisense oligonucleotides to NF-?B using albumin microcapsules in the endotoxic shock model. J Drug Target, 17, 701-709
31. Siwale RC, Oettinger CW, Balakrishna P, Addo R, Uddin N, Siddig A, DSouza MJ. (2008). Formulation and characterization of catalase in albumin microspheres. J Microencapsul, 23, 1-9
32. Siwale RC, Yeboah GK, Addo R, Oettinger CW, DSouza MJ. (2009b). The effect of intracellular antioxidant delivery (catalase) in hydrogen peroxide and proinflammatory cytokine synthesis: a new therapeutic horizon. J Drug Target, 17, 710-718
33. Song HL, Lv S, Liu P. (2009). The roles of tumor necrosis factoralpha in colon tight junction protein expression and intestinal mucosa structure in a mouse model of acute liver failure. BMC Gastroenterol, 9, 70
34. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J; CORTICUS Study Group. (2008). Hydrocortisone therapy for patients with septic shock. N Engl J Med, 358, 111-124
35. Torres R, Macdonald L, Croll SD, Reinhardt J, Dore A, Stevens S, Hylton DM, Rudge JS, Liu-Bryan R, Terkeltaub RA, Yancopoulos GD, Murphy AJ. (2009). Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis, 68, 1602-1608
36. Tracey KJ, Lowry SF, Fahey TJ, Albert JD, Fong Y, Hesse D, Buetler B, Manogue KR, Calvano S, Wei H, Cerami A. (1987). Cachetin/tumor necrosis factor induces lethal shock and stress hormone response in the dog. Surgery, Gynecology and Obstetrics, 164, 415-422 (Pubitemid 17079661)
37. Tsao PW, Suzuki T, Totsuka R, Murata T, Takagi T, Ohmachi Y, Fujimura H, Takata I. (1997). The effect of dexamethasone on the expression of activated NF-?B in adjuvant arthritis. Clin Immun and Immunopathology, 83, 173-178 (Pubitemid 27195937)
38. Uddin MN, Do DP, Pai SB, Gayakwad S, Oettinger CW, DSouza MJ. (2009). A methodology for quantitation and characterization of oligonucleotides in albumin microspheres. Analyst, 134, 1483-1489
39. Yamamoto N, Fukai F, Ohshima H, Terada H, Makino K. (2002). Dependence of phagocytic uptake of polystyrene microspheres by differentiated HL60 upon the size and surface properties of the microspheres. Colloids and Surfaces B: Biointerfaces, 25, 157-162 (Pubitemid 34226686)
40. Zhaowei J, DSouza MJ, Oettinger CW. (2007). Reversal of LPS induced endothelial cell TNF synthesis and increased permeability with microencapsulated antisense oligomers to NF-?B. J Microencapsul, 24, 596-607 (Pubitemid 47180541)